RLAY

Relay TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$17.00

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$13.50

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$8.50

Analysis reference price unavailable

Analysis 2026-05-08 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This is still a monitoring-style T+3 earnings memo, not a conviction upgrade. Primary-source support is solid after the May 5 8-K, 10-Q, and company earnings release, but external revision evidence remains thin. The stock’s anchor moved from $13.03 on 2026-04-28 in the prior baseline to $12.51 on 2026-05-07, which suggests mildly negative post-print digestion even though cash runway improved and milestones stayed on track. With no trustworthy checked evidence of a meaningful post-earnings analyst rerating, the tone stays cautious rather than decisively bullish.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-19catalystQ1 update extended cash runway and kept the zovegalisib calendar activeHigh impact

Relay’s May 5 earnings release said cash, cash equivalents and investments ended Q1 2026 at approximately $642 million and should fund operations into 2029, while also reiterating a May 19 vascular-anomalies data event and ongoing breast-cancer execution. That reduces near-term financing pressure but does not remove clinical-event dependence [#8-K-2026-05-05] [#PR-2026-05-05].

2026-05-20eventInitial vascular anomalies data remain the nearest clean clinical readoutHigh impact

Relay previously guided to initial zovegalisib clinical results in PIK3CA-driven vascular anomalies at ISSVA World Congress 2026 on May 20, 2026, and the May 5 Q1 update again flagged a May 19 conference call during ISSVA. This is the next discrete proof-of-concept checkpoint beyond breast-cancer narrative updates [#PR-2026-04-02] [#PR-2026-05-05].

2027-03-31catalystBreast-cancer program execution still hinges on Phase 3 and frontline triplet follow-throughHigh impact

Relay’s core value driver remains zovegalisib. The company said ReDiscover-2 is ongoing, FDA Breakthrough Therapy designation was granted in February 2026 for the fulvestrant doublet setting, and the zovegalisib plus atirmociclib triplet is the go-forward frontline regimen with a Phase 3 study expected to start in early 2027, subject to regulatory feedback. That is strategically positive, but the setup is still clinical-execution heavy rather than commercially de-risked [#10-Q-2026-05-05] [#PR-2026-05-05] [#8-K-2026-04-27].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology